Resources

Dr. Andrew J.M. Boulton talks with Diabetes in Control Publisher Steve Freed during the AACE 2017 convention in Austin, Texas about the latest diabetes technology that medical professionals should be sure to use. Dr. Andrew J.M. Boulton, MD, DSc, FACP, FRCP is a Professor of Medicine at the University of …

Dr. Andrew J.M. Boulton talks with Diabetes in Control Publisher Steve Freed during the AACE 2017 convention in Austin, Texas about the renal clinic he helped establish in the U.K. Dr. Andrew J.M. Boulton, MD, DSc, FACP, FRCP is a Professor of Medicine at the University of Manchester in England …

Dr. Andrew J.M. Boulton talks with Diabetes in Control Publisher Steve Freed during the AACE 2017 convention in Austin, Texas shares his thoughts of upcoming advances in diabetes treatment. Dr. Andrew J.M. Boulton, MD, DSc, FACP, FRCP is a Professor of Medicine at the University of Manchester in England and …

Dr. Andrew J.M. Boulton talks with Diabetes in Control Publisher Steve Freed during the AACE 2017 convention in Austin, Texas about his personal A1C preference. Dr. Andrew J.M. Boulton, MD, DSc, FACP, FRCP is a Professor of Medicine at the University of Manchester in England and is a visiting professor …

Michael Hill talks with Diabetes in Control Publisher Steve Freed during a Skype interview. In part 8 of this Exclusive Interview, the launch of the Guardian System platform and the Guardian Connect, a standalone system.

In this week's Homerun Slides, a unifying pathophysiologic approach to the complications of diabetes in the context of the beta-cell classification of diabetes.

In a departure from recommendations by cardiology societies, two endocrine groups issue new lipid-management guidelines that bring back LDL-cholesterol targets.

Guest writer David Kliff of Diabetic Investor explains why he doesn't expect any closed-loop systems to expand the overall insulin pump market by any significant amount.

Retrospective analysis presentation shows liraglutide (LIRA) improved glycemic parameters, reduced body weight, BMI, and waist circumference in new T2 patients.

Cheapest treatment associated with increased risks of cardiovascular events and death.